Press Release Details
Exagen Inc. to Participate in December Investor Conferences
Piper Sandler 32nd AnnualVirtual Healthcare Conference ,November 30 –December 3, 2020
A recorded company presentation will be available via the Piper Sandler conference site fromNovember 23 to December 3 , and on theExagen website at: https://investors.exagen.com/events
- Evercore ISI 3rd Annual HealthCONx Conference,
December 1-3, 2020 Exagen President and CEORon Rocca will participate in a Fireside Chat onWednesday, December 2, 2020 , at10:30 am EST . A link to the live webcast of the Fireside Chat will be posted to theExagen website at: https://investors.exagen.com/events
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com.
Investors
Mike.Cavanaugh@westwicke.com
646.677.1838
Company
kadawi@exagen.com
760.477.5514
Source: Exagen Inc.